Follow Ciliatech’s past history and latest exciting developments via the news stories below.
Ciliatech were delighted to join Mr. Andrew Tatham in his operating room (OR) as he performed the first ever Intercil® Uveal Spacer implantation in the UK following the recent EU MDR CE Mark approval of the product. Mr. Tatham has previously commented: “The supraciliary space offers a viable and advantageous
Just weeks after confirming EU MDR CE Mark approval for our novel Intercil Uveal Spacer, Ciliatech are thrilled to announce that Dr. Karsten Klabe becomes the first ever surgeon in the world to have implanted Intercil® at his specialist eye surgery centre in Dusseldorf, Germany. Dr. Klabe commented: “It is
Ciliatech obtains CE mark for eye implant Intercil® Uveal Spacer, novel treatment for patients with glaucoma Innovative implant that lowers IOP without penetrating anterior chamber set to be game changer in surgical treatment of both open and narrow angle glaucoma CE mark pivotal step in paving way for Intercil’s commercial
Ciliatech are delighted to announce the appointment of Coen Van Der Steur as International Business Development Consultant, joining the company to support its global commercial organisation and reporting directly to Sahil Syed, VP Sales & Marketing. In his new role, Coen will lead business development activities across the Middle East,
Ciliatech are delighted to announce the appointment of Gabriele (‘Gabi’) Grubert as Senior Surgical Glaucoma Sales Specialist for the DACH region, joining the company to strengthen its commercial organisation across one of Europe’s most important ophthalmology markets. In her new role, Gabi will lead commercial activities across Germany, Austria and
Exploring a novel class of glaucoma surgery that targets the supraciliary space. BY ANDREW J. TATHAM, MD, MBA MIGS has transformed glaucoma care by enabling earlier surgical intervention, improved IOP control, and reduced dependence on long-term medical therapy. Although MIGS procedures that target the trabecular meshwork (TM) and Schlemm canal
Published by Eye News, the longest-standing magazine dedicated to ophthalmology in the UK. Ciliatech will leverage ophthalmic expertise of seven-member advisory board to bring to market Intercil® Uveal Spacer, a novel glaucoma implant offering unique benefits to eye surgeons and patients across the globe Chavanod (near Annecy), France, November 12,
Ciliatech CEO Olivier Benoit travelled to Shanghai, China last week – a country that is a key future target market owing to the disproportionately high prevalence of Angle Closure Glaucoma (an indication which Ciliatech are actively pursuing for their Intercil® Uveal Spacer). He was pleased to collect the ‘Patient Impact
Major event for advancing innovation in eye care gives Ciliatech first-time opportunity to show US ophthalmic audiences potential of treating open and narrow angle glaucoma in supraciliary space with single device Chavanod (near Annecy), France, October 10, 2024 – Ciliatech, an innovative medtech company focusing on the treatment of glaucoma,
Results presented at Ophthalmology Futures European Forum will show: • Sustained IOP (intraocular pressure) control of 8.0mmHg/33% reduction vs baseline • 70% reduction in medication dependance among patients • 68% of patients remain medication-free at three years, with no significant safety reports Ophthalmology Futures Forums, Barcelona, Spain, September 5, 2024
This site is only for the use of professionals associated with the field of Ophthalmology and is not intended for patients.